| 1 |
35144966 | Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. | 2022 May 2 |
1 |
| 2 |
33258078 | Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. | 2021 Apr |
1 |
| 3 |
33332933 | Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). | 2021 Jul |
1 |
| 4 |
33682068 | Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review. | 2021 Apr |
8 |
| 5 |
33800852 | Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. | 2021 Mar 6 |
2 |
| 6 |
33833890 | Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer. | 2021 |
2 |
| 7 |
33905134 | Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. | 2021 Apr 27 |
1 |
| 8 |
34058187 | Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. | 2021 Aug |
2 |
| 9 |
34190995 | Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. | 2021 Jun 1 |
1 |
| 10 |
31618131 | Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. | 2020 Apr 20 |
2 |
| 11 |
32352244 | Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. | 2020 Jul |
1 |
| 12 |
32690611 | A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing HER2 expression in breast cancer. | 2020 Oct 9 |
3 |
| 13 |
32756099 | Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. | 2020 Jul 31 |
1 |
| 14 |
32843722 | The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. | 2020 Oct |
2 |
| 15 |
33052961 | HER2-mediated enhancement of Ebola virus entry. | 2020 Oct |
1 |
| 16 |
30531871 | Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. | 2019 Feb |
1 |
| 17 |
31183434 | Lipoproteins modulate growth and P-glycoprotein expression in drug-resistant HER2-overexpressed breast cancer cells. | 2019 Apr |
1 |
| 18 |
31932263 | Quantitative assessment of CD68+ AND CD163+ macrophages in the primary focus and metastatic lesions of regional lymph nodes in non-luminal her2-positive invasive breast carcinoma | 2019 Oct 31 |
1 |
| 19 |
28786348 | Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required. | 2018 |
2 |
| 20 |
29383628 | Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. | 2018 Jun |
1 |
| 21 |
29720121 | C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells. | 2018 May 2 |
7 |
| 22 |
29940172 | Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. | 2018 Nov |
1 |
| 23 |
30358233 | Should addition of five years of ovarian suppression to tamoxifen be "must" for hormone receptor positive and HER-2 positive breast cancer under the age of 35? | 2018 Jul-Aug |
1 |
| 24 |
30458882 | HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women. | 2018 Nov 20 |
1 |
| 25 |
30583472 | Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy. | 2018 Dec 21 |
2 |
| 26 |
31149534 | Tamoxifen withdrawal in women with progressive metastatic breast cancer: a case series of six patients. | 2018 Oct |
2 |
| 27 |
27137076 | Breast Cancer: Current Molecular Therapeutic Targets and New Players. | 2017 |
1 |
| 28 |
27721408 | Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. | 2017 Apr |
1 |
| 29 |
27879270 | Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression. | 2017 Jan 15 |
2 |
| 30 |
27942916 | Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells. | 2017 Jan |
5 |
| 31 |
27966906 | Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles. | 2017 Jan 24 |
1 |
| 32 |
28100469 | Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. | 2017 Mar |
1 |
| 33 |
28416639 | Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. | 2017 Nov |
1 |
| 34 |
28494403 | HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. | 2017 Jul |
7 |
| 35 |
28498399 | Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. | 2017 Jun |
2 |
| 36 |
28601930 | Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. | 2017 Sep |
1 |
| 37 |
28637868 | Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. | 2017 Aug 18 |
4 |
| 38 |
28881721 | Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. | 2017 Aug 8 |
5 |
| 39 |
29760748 | Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables. | 2017 Winter |
1 |
| 40 |
26581908 | Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. | 2016 May |
2 |
| 41 |
26662961 | The effects of bufadienolides on HER2 overexpressing breast cancer cells. | 2016 Jun |
3 |
| 42 |
26771508 | HER2 Targeted Breast Cancer Therapy with Switchable "Off/On" Multifunctional "Smart" Magnetic Polymer Core-Shell Nanocomposites. | 2016 Jan 27 |
2 |
| 43 |
26792291 | A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis. | 2016 Feb |
1 |
| 44 |
26803986 | HOX genes: Major actors in resistance to selective endocrine response modifiers. | 2016 Apr |
1 |
| 45 |
26884313 | Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. | 2016 Jul |
5 |
| 46 |
26959415 | Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. | 2016 |
2 |
| 47 |
27044936 | Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. | 2016 Jul 1 |
1 |
| 48 |
27573917 | NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. | 2016 Nov |
5 |
| 49 |
27695927 | Erratum to: NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells. | 2016 Nov |
2 |
| 50 |
23479208 | Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. | 2015 Jan |
1 |